Article thumbnail
Location of Repository

Inhibition of multiple sclerosis–associated retrovirus as biomarker of interferon therapy

By Giuseppe Mameli, Caterina Serra, Vito Astone, Massimiliano Castellazzi, Luciana Poddighe, Enrico Fainardi, Walter Neri, Enrico Granieri and Antonina Dolei


The authors performed a longitudinal evaluation of multiple sclerosis (MS) patients, during 1 year of therapy with interferon-<i>β</i> (IFN-<i>β</i>), by clinical examination and detection of presence in the blood and viral load of MS-associated retrovirus (MSRV), by MSRV<i>env</i>-specific, fully quantitative, real time reverse transcriptase–polymerase chain reaction (RT-PCR). MSRV load in the blood was directly related to MS duration and fell below detection limits within 3 months of IFN therapy; one patient had strong progression, accompanied by total MSRV rescue. These findings suggest that evaluation of plasmatic MSRV could be considered the first prognostic marker for the individual patient, to monitor disease progression and therapy outcome

Topics: MED/07 Microbiologia e microbiologia clinica
Publisher: Springer
Year: 2008
OAI identifier:
Provided by: UnissResearch
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.